Research programme: antipsychotic therapeutics - Pfizer
Alternative Names: Compound 22; WAY-162545; WAY-163909; WAY-261240; WAY-629Latest Information Update: 27 Sep 2011
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Chromans; Small molecules
- Mechanism of Action Serotonin 2C receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psychotic disorders
Most Recent Events
- 16 Oct 2009 Wyeth has been acquired by Pfizer
- 20 Aug 2009 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Schizophrenia presented at the 238th National Meeting of the American Chemical Society (238th-ACS-2009) ,
- 16 Aug 2009 Preclinical trials in Psychotic disorders in USA (PO)